Open AccessPatterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
Author(s) -
Justin F. Gainor,
Diane Tseng,
Satoshi Yoda,
Ibiayi DagogoJack,
Luc Friboulet,
Jessica J. Lin,
Harper Hubbeling,
Leila Dardaei,
Anna F. Farago,
Katherine R. Schultz,
Lorin A. Ferris,
Zofia Piotrowska,
James S. Hardwick,
Donghui Huang,
Mari Mino–Kenudson,
A. John Iafrate,
Aaron N. Hata,
Beow Y. Yeap,
Alice T. Shaw
Publication year - 2017
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.17.00063
Subject(s) - crizotinib , ros1 , medicine , brain metastasis , lung cancer , anaplastic lymphoma kinase , oncology , cancer , metastasis , adenocarcinoma , pathology , cancer research , gastroenterology , malignant pleural effusion
The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1-2% of non-small cell lung cancer (NSCLC), conferring sensitivity to treatment with the ALK/ROS1/MET inhibitor crizotinib. Currently, insights into patterns of metastatic spread and mechanisms of crizotinib resistance among ROS1 -positive patients are limited.